Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Altimmune

BioNTech SE

IMV Inc

Inovio Pharmaceuticals

Good news for Moderna was bad news for several of its rivals.

Why Several Coronavirus Vaccine Stocks Not Named Moderna Fell Today

NEW YORK, July 13, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ: SRNE) and certain of its officers. The class action, filed in United States District Court for the Southern...

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sorrento Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRNE

SAN DIEGO--(BUSINESS WIRE)---- $SRNE #ClassAction--Shareholder rights law firm Robbins LLP announces that it is investigating Sorrento Therapeutics, Inc. (NASDAQ: SRNE) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Sorrento is a clinical stage biopharma company that develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. If you suffered a loss as a result of Sorrento's mis

Shareholder Alert: Robbins LLP Announces It Is Investigating Sorrento Therapeutics, Inc. (SRNE) for Misleading Shareholders

As of late, it has definitely been a great time to be an investor in Sorrento Therapeutics

Will Sorrento Therapeutics' Shares March Higher, Can It Continue?

While there's still much scientific research to be done, Sorrento has built an intriguing case for both its Covid-19 antibody and SRNE stock.
The post Sorrento: Making Sense of the Latest Covid-19 Stock appeared first on InvestorPlace.

Sorrento: Making Sense of the Latest Covid-19 Stock

The biotech is making progress with its COVID-19 products.

Here's Why Sorrento Therapeutics Skyrocketed 24% Higher in June

The COVID-19 antibody-focused company has a promising new coronavirus vaccine candidate.

Why Sorrento Therapeutics Stock (SRNE) Jumped Today

SAN DIEGO, July  01, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has published a pre-print publication (https://www.biorxiv.org/content/10.1101/2020.06.29.178616v1.full.pdf) describing initial pre-clinical results from its COVID-19 vaccination program, which introduced a novel targeted protein vaccine against COVID-19, referred to as T-VIVA-19.

Sorrento Announces Selection of T-VIVA-19™ as Targeted Protein Vaccine Candidate for SARS-CoV-2

New York, New York--(Newsfile Corp. - June 29, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ: SRNE) of the July 27, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.If you invested in Sorrento stock or options between Ma

Sorrento Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Sorrento Therapeutics, Inc. To Contact The Firm

Does the biotech company really have a cure for COVID-19 on its hands?

Why Is Everyone Talking About Sorrento Therapeutics Stock?

New York, New York--(Newsfile Corp. - June 26, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" or the "Company") of the July 27, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logo

Sorrento Deadline Alert.: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Sorrento Therapeutics, Inc. To Contact The Firm

Vaxart

Investors are piling into coronavirus stocks as COVID-19 cases surge.

Why Vaxart, Inovio, and Sorrento Therapeutics Stocks Soared Today

Block

McCormick

McCormick, Sorrento, Square and Inovio were our top stock trades from Thursday. So, let's look at the charts to see what's going on now.

4 Top Stock Trades for Friday: SQ, INO, MKC, SRNE

Moderna

As COVID-19 cases surge, investors bid up coronavirus vaccine and treatment stocks.

Why Inovio, Moderna, and Sorrento Therapeutics Stocks Rose Today

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Sorrento Therapeutics, Inc. ("Sorrento” or "the Company") (NASDAQ: SRNE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Sorrento securities between May 15, 2020 through May 22, 2020, inclusive (the ''Class Period''). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/srne. This

SRNE Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Sorrento Therapeutics, Inc. and Encourages Investors With Losses Exceeding 250K to Contact the Firm

New York, New York--(Newsfile Corp. - June 23, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" or the "Company")of the July 27, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi LogoIf you invested in

Sorrento Deadline Alert:  Faruqi  & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Sorrento Therapeutics, Inc. To Contact The Firm

Gilead Sciences

Sorrento has more momentum right now. But does Gilead's pipeline and dividend make it the better pick?

Better Coronavirus Stock: Gilead Sciences vs. Sorrento Therapeutics

New York, New York--(Newsfile Corp. - June 22, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" or the "Company") of the July 27, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi LogoIf you invested in

Sorrento Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Sorrento Therapeutics, Inc. To Contact The Firm

Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Sorrento Therapeutics (SRNE) Stock?

Regeneron Pharmaceuticals

It's a battle of big vs. little with these two COVID-19-focused biotechs.

Better Coronavirus Stock: Sorrento Therapeutics vs. Regeneron

Sorrento’s in vitro data show its coronavirus candidates block infection. But a product to test in humans is much farther down the road.

Should Sorrento Therapeutics Be Your Next Coronavirus Buy?

SAN DIEGO, June  12, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it prepaid in full its outstanding term loans on June 12, 2020.

Sorrento Announces Full Repayment of Outstanding Term Loans

The company could receive regulatory approval for its coronavirus antibody test.

Why Sorrento Therapeutics Stock Is Up Today

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares were headed higher Thursday following an announcement concerning its antibody test kit for SARS-CoV-2, the virus that causes COVID-19.

Sorrento Rallies On EUA Filing For Rapid COVID-19 Antibody Test Kit

SAN DIEGO, June  10, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that an Application for Emergency Use Authorization (EUA) is under review at the U.S. Food and Drug Administration (FDA) for its COVI-TRACKTM in vitro diagnostic test kit for the independent detection of IgG and IgM antibodies in sera of patients exposed to the SARS-CoV-2 virus.

Sorrento Announces It Has Submitted an Emergency Use Authorization (EUA) Application for the COVI-TRACK Diagnostic Test for the Detection of Antibodies to SARS-CoV-2

News for Sorrento Therapeutics Inc Stock (SRNE)